B D Kayser1,2,3, M Lhomme1, M C Dao1,2,3, F Ichou1, J-L Bouillot4, E Prifti1, A Kontush1,5,6, J-M Chevallier7, J Aron-Wisnewsky1,2,3, I Dugail1,2,3, K Clément1,2,3. 1. Nutriomics Team, Institute of Cardiometabolism and Nutrition, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France. 2. Nutriomics Team, INSERM, UMR S U1166, Paris, France. 3. Nutriomics Team, Sorbonne Universités, UPMC University Paris 06, UMR_S 1166, Paris, France. 4. Visceral Surgery Department, Assistance Publique-Hôpitaux de Paris, Ambroise Paré, Paris, France. 5. Dyslipidemia, Inflammation, and Atherosclerosis Team, INSERM, UMR_S U1166, Paris, France. 6. Dyslipidemia, Inflammation, and Atherosclerosis Team, Sorbonne Universités, UPMC Université Paris 06, UMR_S 1166, Institute of Cardiometabolism and Nutrition, Paris, France. 7. Visceral Surgery Department, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.
Abstract
BACKGROUND/ OBJECTIVES: Circulating phospholipids and sphingolipids are implicated in obesity-related comorbidities such as insulin resistance and cardiovascular disease. How bariatric surgery affects these important lipid markers is poorly understood. We sought to determine whether Roux-en-Y gastric bypass (RYGB), which is associated with greater metabolic improvement, differentially affects the phosphosphingolipidome compared with adjustable gastric banding (AGB). SUBJECTS/ METHODS: Fasting sera were available from 59 obese women (body mass index range 37-51 kg m-2; n=37 RYGB and 22 AGB) before surgery, then at 1 (21 RYGB, 12 AGB) and 3 months follow-up (19 RYGB, 12 AGB). HPLC-MS/MS was used to quantify 131 lipids from nine structural classes. DXA measurements and laboratory parameters were also obtained. The associations between lipids and clinical measurements were studied with P-values adjusted for the false discovery rate (FDR). RESULTS: Both surgical procedures rapidly induced weight loss and improved clinical profiles, with RYGB producing better improvements in fat mass, and serum total cholesterol, low-density lipoprotein-cholesterol (LDL-C) and orosomucoid (FDR <10%). Ninety-three (of 131) lipids were altered by surgery-the majority decreasing-with 29 lipids differentially affected by RYGB during the study period. The differential effect of the surgeries remained statistically significant for 20 of these lipids after adjusting for differences in weight loss between surgery types. The RYGB signature consisted of phosphatidylcholine species not exceeding 36 carbons, and ceramides and sphingomyelins containing C22 to C25 fatty acids. RYGB also led to a sustained increase in unsaturated ceramide and sphingomyelin species. The RYGB-specific lipid changes were associated with decreases in body weight, total and LDL-C, orosomucoid and increased HOMA-S (FDR <10%). CONCLUSIONS: Concomitant with greater metabolic improvement, RYGB induced early and sustained changes in phosphatidylcholines, sphingomyelins and ceramides that were independent of greater weight loss. These data suggest that RYGB may specifically alter sphingolipid metabolism, which, in part, could explain the better metabolic outcomes of this surgical procedure.
BACKGROUND/ OBJECTIVES: Circulating phospholipids and sphingolipids are implicated in obesity-related comorbidities such as insulin resistance and cardiovascular disease. How bariatric surgery affects these important lipid markers is poorly understood. We sought to determine whether Roux-en-Y gastric bypass (RYGB), which is associated with greater metabolic improvement, differentially affects the phosphosphingolipidome compared with adjustable gastric banding (AGB). SUBJECTS/ METHODS: Fasting sera were available from 59 obesewomen (body mass index range 37-51 kg m-2; n=37 RYGB and 22 AGB) before surgery, then at 1 (21 RYGB, 12 AGB) and 3 months follow-up (19 RYGB, 12 AGB). HPLC-MS/MS was used to quantify 131 lipids from nine structural classes. DXA measurements and laboratory parameters were also obtained. The associations between lipids and clinical measurements were studied with P-values adjusted for the false discovery rate (FDR). RESULTS: Both surgical procedures rapidly induced weight loss and improved clinical profiles, with RYGB producing better improvements in fat mass, and serum total cholesterol, low-density lipoprotein-cholesterol (LDL-C) and orosomucoid (FDR <10%). Ninety-three (of 131) lipids were altered by surgery-the majority decreasing-with 29 lipids differentially affected by RYGB during the study period. The differential effect of the surgeries remained statistically significant for 20 of these lipids after adjusting for differences in weight loss between surgery types. The RYGB signature consisted of phosphatidylcholine species not exceeding 36 carbons, and ceramides and sphingomyelins containing C22 to C25 fatty acids. RYGB also led to a sustained increase in unsaturated ceramide and sphingomyelin species. The RYGB-specific lipid changes were associated with decreases in body weight, total and LDL-C, orosomucoid and increased HOMA-S (FDR <10%). CONCLUSIONS: Concomitant with greater metabolic improvement, RYGB induced early and sustained changes in phosphatidylcholines, sphingomyelins and ceramides that were independent of greater weight loss. These data suggest that RYGB may specifically alter sphingolipid metabolism, which, in part, could explain the better metabolic outcomes of this surgical procedure.
Authors: Laurent Camont; Marie Lhomme; Fabiana Rached; Wilfried Le Goff; Anne Nègre-Salvayre; Robert Salvayre; Catherine Calzada; Michel Lagarde; M John Chapman; Anatol Kontush Journal: Arterioscler Thromb Vasc Biol Date: 2013-10-03 Impact factor: 8.311
Authors: Sean P Heffron; Amar Parikh; Alexandar Volodarskiy; Christine Ren-Fielding; Arthur Schwartzbard; Joseph Nicholson; Sripal Bangalore Journal: Am J Med Date: 2016-02-18 Impact factor: 4.965
Authors: Sarah M Turpin; Hayley T Nicholls; Diana M Willmes; Arnaud Mourier; Susanne Brodesser; Claudia M Wunderlich; Jan Mauer; Elaine Xu; Philipp Hammerschmidt; Hella S Brönneke; Aleksandra Trifunovic; Giuseppe LoSasso; F Thomas Wunderlich; Jan-Wilhelm Kornfeld; Matthias Blüher; Martin Krönke; Jens C Brüning Journal: Cell Metab Date: 2014-10-07 Impact factor: 27.287
Authors: Hazel Huang; Takhar Kasumov; Patrick Gatmaitan; Helen M Heneghan; Sangeeta R Kashyap; Philip R Schauer; Stacy A Brethauer; John P Kirwan Journal: Obesity (Silver Spring) Date: 2011-05-05 Impact factor: 5.002
Authors: David M Mutch; Jens C Fuhrmann; Dietrich Rein; Jan C Wiemer; Jean-Luc Bouillot; Christine Poitou; Karine Clément Journal: PLoS One Date: 2009-11-19 Impact factor: 3.240
Authors: Alexander Sigruener; Marcus E Kleber; Susanne Heimerl; Gerhard Liebisch; Gerd Schmitz; Winfried Maerz Journal: PLoS One Date: 2014-01-17 Impact factor: 3.240
Authors: Rebekah J Nicholson; Marie K Norris; Annelise M Poss; William L Holland; Scott A Summers Journal: Annu Rev Nutr Date: 2022-05-18 Impact factor: 9.323
Authors: Bruno Ramos-Molina; Daniel Castellano-Castillo; Oscar Pastor; Luis Ocaña-Wilhelmi; Diego Fernández-García; Manuel Romero-Gómez; Fernando Cardona; Francisco J Tinahones Journal: Obes Surg Date: 2019-03 Impact factor: 4.129
Authors: Judith Aron-Wisnewsky; Edi Prifti; Eugeni Belda; Farid Ichou; Brandon D Kayser; Maria Carlota Dao; Eric O Verger; Lyamine Hedjazi; Jean-Luc Bouillot; Jean-Marc Chevallier; Nicolas Pons; Emmanuelle Le Chatelier; Florence Levenez; Stanislav Dusko Ehrlich; Joel Dore; Jean-Daniel Zucker; Karine Clément Journal: Gut Date: 2018-06-13 Impact factor: 23.059
Authors: Malou A H Nuijten; Thijs M H Eijsvogels; Valerie M Monpellier; Ignace M C Janssen; Eric J Hazebroek; Maria T E Hopman Journal: Obes Rev Date: 2021-10-19 Impact factor: 10.867
Authors: Stephen L Atkin; Vimal Ramachandran; Noha A Yousri; Manasi Benurwar; Steven C Simper; Rodrick McKinlay; Ted D Adams; S Hani Najafi-Shoushtari; Steven C Hunt Journal: Front Endocrinol (Lausanne) Date: 2019-01-04 Impact factor: 5.555